Déglon N - Search Results

1

Aebischer P, Hottinger AF, Déglon N. Aebischer P, et al. Among authors: deglon n. Nat Med. 1999 Aug;5(8):852. doi: 10.1038/11271. Nat Med. 1999. PMID: 10426290 No abstract available.

2

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.

Aebischer P, Schluep M, Déglon N, Joseph JM, Hirt L, Heyd B, Goddard M, Hammang JP, Zurn AD, Kato AC, Regli F, Baetge EE. Aebischer P, et al. Among authors: deglon n. Nat Med. 1996 Jun;2(6):696-9. doi: 10.1038/nm0696-696. Nat Med. 1996. PMID: 8640564 Clinical Trial.

3

Presence of Gal-alpha1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology.

Déglon N, Aubert V, Spertini F, Winkel L, Aebischer P. Déglon N, et al. Xenotransplantation. 2003 May;10(3):204-13. doi: 10.1034/j.1399-3089.2003.00110.x. Xenotransplantation. 2003. PMID: 12694540

4

Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy.

Schwenter F, Déglon N, Aebischer P. Schwenter F, et al. Among authors: deglon n. J Gene Med. 2003 Mar;5(3):246-57. doi: 10.1002/jgm.338. J Gene Med. 2003. PMID: 12666190

5

Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.

Bensadoun JC, Déglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Bensadoun JC, et al. Among authors: deglon n. Exp Neurol. 2000 Jul;164(1):15-24. doi: 10.1006/exnr.2000.7409. Exp Neurol. 2000. PMID: 10877911

6

Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus.

Hottinger AF, Azzouz M, Déglon N, Aebischer P, Zurn AD. Hottinger AF, et al. Among authors: deglon n. J Neurosci. 2000 Aug 1;20(15):5587-93. doi: 10.1523/JNEUROSCI.20-15-05587.2000. J Neurosci. 2000. PMID: 10908595 Free PMC article.

7

Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions.

Schwenter F, Schneider BL, Pralong WF, Déglon N, Aebischer P. Schwenter F, et al. Among authors: deglon n. Hum Gene Ther. 2004 Jul;15(7):669-80. doi: 10.1089/1043034041361172. Hum Gene Ther. 2004. PMID: 15242527

8

Gene transfer techniques for the delivery of GDNF in Parkinson's disease.

Ridet JL, Déglon N, Aebischer P. Ridet JL, et al. Among authors: deglon n. Novartis Found Symp. 2000;231:202-15; discussion 215-9, 302-6. doi: 10.1002/0470870834.ch13. Novartis Found Symp. 2000. PMID: 11131539 Review.

9

Lentiviruses as vectors for CNS diseases.

Déglon N, Aebischer P. Déglon N, et al. Curr Top Microbiol Immunol. 2002;261:191-209. doi: 10.1007/978-3-642-56114-6_10. Curr Top Microbiol Immunol. 2002. PMID: 11892248 Review. No abstract available.

10

Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts.

Régulier E, Schneider BL, Déglon N, Beuzard Y, Aebischer P. Régulier E, et al. Among authors: deglon n. Gene Ther. 1998 Aug;5(8):1014-22. doi: 10.1038/sj.gt.3300687. Gene Ther. 1998. PMID: 10326023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters